Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,228 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,228 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01056601 | Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy | Phase 2 | terminated | Jan 26, 2010 | Masonic Cancer Center, University of Minnesota | Funding not available | Funding |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced…(ARTEMIS-Eso) | Phase 1 / Phase 2 | withdrawn | Oct 12, 2017 | Jules Bordet Institute | Suspended collaboration with the company providing the study drug | Sponsor / business decision |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib… | Phase 2 | withdrawn | Apr 2, 2015 | Delcath Systems Inc. | No enrollment in the study | Enrollment / accrual |
| NCT02182466 | German Colon Capsule Registry(DEKOR) | — | terminated | Jul 8, 2014 | Johann Wolfgang Goethe University Hospital | not stated | Not stated |
| NCT00226941 | A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and… | Phase 1 / Phase 2 | terminated | Sep 27, 2005 | George Albert Fisher | The response rate observed in the phase 1 portion of the study did not merit further evaluation in… | Other (stated, no rule matched) |
| NCT01279681 | Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older… | Phase 3 | terminated | Jan 19, 2011 | Alliance for Clinical Trials in Oncology | Slow accrual | Enrollment / accrual |
| NCT03001505 | Registry for Pancreatic Cancer | — | withdrawn | Dec 23, 2016 | Duke University | Study design changed to clinical database only with no research question to be studied. | Other (stated, no rule matched) |
| NCT00463840 | Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic… | Phase 1 / Phase 2 | terminated | Apr 20, 2007 | NYU Langone Health | Due to slow accrual | Enrollment / accrual |
| NCT00623077 | MT2004-30: Tomotherapy for Solid Tumors | Phase 1 | terminated | Feb 25, 2008 | Masonic Cancer Center, University of Minnesota | Replaced by another study | Other (stated, no rule matched) |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | Phase 1 | terminated | May 2, 2003 | Masonic Cancer Center, University of Minnesota | Withdrawn due to slow accrual | Enrollment / accrual |
| NCT02057991 | Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal… | N/A | terminated | Feb 7, 2014 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy… | Phase 2 | terminated | May 18, 2009 | Alliance for Clinical Trials in Oncology | Slow accrual | Enrollment / accrual |
| NCT02549755 | 11C-acetate for Treatment Response After Radiotherapy for HCC | Phase 2 | terminated | Sep 15, 2015 | Justin Sims | Poor enrollment | Enrollment / accrual |
| NCT00003530 | Antineoplaston Therapy in Treating Patients With Primary Liver Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT01334710 | A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer | Phase 2 | terminated | Apr 13, 2011 | Emory University | safety issue observed on another hepatocellular study using OSI906 | Safety / toxicity |
| NCT00625183 | Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients… | Phase 2 | terminated | Feb 28, 2008 | Roswell Park Cancer Institute | Withdrawn due to poor/low accrual | Enrollment / accrual |
| NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)(HepSTAR) | Phase 2 | terminated | Nov 8, 2016 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | lack of recruitment | Enrollment / accrual |
| NCT00753441 | Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the…(STENTBY) | N/A | terminated | Sep 16, 2008 | Heidelberg University | Low patient accrual | Enrollment / accrual |
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | Phase 2 | terminated | May 25, 2012 | Mayo Clinic | pending expiration of the supply of study agent. | Drug supply |
| NCT02106871 | Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer(PCC) | Phase 1 | withdrawn | Apr 8, 2014 | The University of Texas Medical Branch, Galveston | Study did not get funded. Study never started | Funding |
| NCT02630420 | Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer | Phase 1 | withdrawn | Dec 15, 2015 | Yale University | The study never officially funded and therefore never began. | Funding |
| NCT02157363 | POsitioning for Esophageal Cancer Resection(POETRI) | N/A | terminated | Jun 6, 2014 | Technische Universität Dresden | poor recruitment due to change of surgical technique | Enrollment / accrual |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients…(HCC DC CTL) | Phase 1 / Phase 2 | suspended | Jan 3, 2014 | HRYZ Biotech Co. | Interim analysis | Efficacy / futility |
| NCT01688336 | FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | Phase 2 | terminated | Sep 19, 2012 | UNC Lineberger Comprehensive Cancer Center | Results unlikely to impact treatment patterns. Time to complete not justified. | Other (stated, no rule matched) |
| NCT01768988 | Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized…(PANPAIN/1) | Phase 4 | terminated | Jan 16, 2013 | Parc de Salut Mar | Change of PI. Former PI changed from Research Center and Promoter obliged unexpectedly to change… | Other (stated, no rule matched) |
| NCT02774512 | Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in…(ZAK-0) | Early Phase 1 | withdrawn | May 17, 2016 | Institut Bergonié | none participant has been enrolled and recruited during the first year after competent autority… | Enrollment / accrual |
| NCT03007771 | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild… | Phase 1 | withdrawn | Jan 2, 2017 | Washington University School of Medicine | Decision was made to not go forward with the study | Other (stated, no rule matched) |
| NCT02066363 | Study of Parenteral Nutrition to Patients With Gastrointestinal Cancer | N/A | terminated | Feb 19, 2014 | Odense University Hospital | Recruitment very time consuming, too few wanting participation | Enrollment / accrual |
| NCT00003522 | Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT00003485 | Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT01065818 | Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET | N/A | terminated | Feb 9, 2010 | Columbia University | Lack of funding | Funding |
| NCT02615574 | A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With… | Phase 2 | withdrawn | Nov 26, 2015 | Pawel Kalinski | Due to inadequate supply of drug | Drug supply |
| NCT02542436 | Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical… | — | withdrawn | Sep 7, 2015 | Hoffmann-La Roche | not stated | Not stated |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | Phase 1 | terminated | Sep 2, 2015 | Merrimack Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT02585687 | Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the…(ETAFIRM) | N/A | terminated | Oct 23, 2015 | Hospices Civils de Lyon | problems with enrollment | Enrollment / accrual |
| NCT01489410 | Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma | N/A | withdrawn | Dec 9, 2011 | University of Minnesota | Insufficient staff | Other (stated, no rule matched) |
| NCT02609451 | Closure of Protective Ileostomy 2 vs. 12 Weeks After TME(Closure2vs12) | N/A | terminated | Nov 20, 2015 | Kantonsspital Liestal | Evidence of bad outcome after interims analysis | Other (stated, no rule matched) |
| NCT03264274 | Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal…(AUSCOR) | Phase 2 | withdrawn | Aug 29, 2017 | Barts & The London NHS Trust | Funding restrictions - study never opened to recruitment | Enrollment / accrual |
| NCT01531712 | Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially… | Phase 2 | terminated | Feb 13, 2012 | Institut Català d'Oncologia | Due to a low recruitment rate since start of recruitment period. | Enrollment / accrual |
| NCT01740375 | Role of Esophagectomy in Complete Responders to CCRT(ESOPRESSO) | Phase 3 | terminated | Dec 4, 2012 | Asan Medical Center | slow recruitment | Enrollment / accrual |
| NCT02345746 | Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in… | Phase 2 | withdrawn | Jan 26, 2015 | Western Regional Medical Center | patient population | Other (stated, no rule matched) |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein… | Phase 1 | terminated | Aug 17, 2012 | Merck KGaA, Darmstadt, Germany | The sponsor decided not to conduct the expansion part of trial (part 2) | Sponsor / business decision |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | Phase 2 | terminated | Jul 1, 2016 | Chinese University of Hong Kong | Poor case accrual | Enrollment / accrual |
| NCT01191385 | GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar… | — | withdrawn | Aug 30, 2010 | Bayer | Study is officially cancelled bevore FPFV. | Other (stated, no rule matched) |
| NCT02959359 | DAA in the Risk of Recurrence After Curative Treatment of HCC | Phase 4 | withdrawn | Nov 9, 2016 | Taipei Veterans General Hospital, Taiwan | The supplies of study drug were halted by Gilead Sciences Ltd. | Other (stated, no rule matched) |
| NCT01114256 | FNA Tumor Sampling for CD137 Modulation: A Pilot Study | — | terminated | May 3, 2010 | Stanford University | not stated | Not stated |
| NCT00386516 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile… | Phase 2 | withdrawn | Oct 11, 2006 | Galectin Therapeutics Inc. | Financing and re-organization | Funding |
| NCT02079220 | A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX)… | Phase 2 | withdrawn | Mar 5, 2014 | James J Lee | Funding for the study was withdrawn, no participants were ever recruited. | Enrollment / accrual |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT02651727 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and… | Phase 1 | terminated | Jan 11, 2016 | Verastem, Inc. | the company's decision to de-prioritize 4718 development | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Dec 28, 2017source: clinicaltrials